Marker Therapeutics Stock Forecast
NASDAQ: MRKRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MRKR analyst consensus
Consensus (3 analysts)
none
Avg. price target
$7.87+710.00%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Marker Therapeutics (2026-10-09), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $7.87, with a high estimate of $10.00 and a low estimate of $5.60. The average target implies upside of 710.0% from the current price of $0.9716.
The spread between the highest and lowest targets is 78.6%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MRKR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.60 | +476.37% |
| Average target | $7.87 | +710.00% |
| High target | $10.00 | +929.23% |